Premium
Adrenomedullin, Bcl‐2 and microvessel density in normal, hyperplastic and neoplastic endometrium
Author(s) -
Nunobiki Osamu,
Nakamura Misa,
Taniguchi Emiko,
Utsunomiya Hirotoshi,
Mori Ichiro,
Tsubota Yukari,
Mabuchi Yoshiya,
Kakudo Kennichi
Publication year - 2009
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1111/j.1440-1827.2009.02403.x
Subject(s) - adrenomedullin , atypia , hyperplasia , angiogenesis , endometrium , immunoperoxidase , microvessel , endometrial hyperplasia , pathology , endocrinology , receptor , medicine , immunology , antibody , monoclonal antibody
Adrenomedullin (ADM) is a multifunctional 52‐amino acid peptide involved in numerous physiological and pathological processes, including angiogenesis, growth regulation, differentiation, and vasodilation. ADM is thought to act through the G protein‐coupled receptor calcitonin receptor‐like receptor, with specificity being conferred by receptor‐associated modifying protein 2. The aim of the present study was to clarify the roles of ADM status, and tumor vessels in endometrium. Specimens were examined for ADM, microvessel density (MVD), area of venules (AV) and Bcl‐2 oncoprotein using an immunoperoxidase method. The difference of ADM between normal proliferative phase and hyperplasia without atypia was significant ( P < 0.05). The level of Bcl‐2 was significantly different between hyperplasia without atypia and hyperplasia with atypia ( P < 0.05). ADM, MVD and AV in the endometrium increased in a stepwise manner from normal, simple or complex hyperplasia with or without atypia to grade 1 adenocarcinoma. In contrast, expression of Bcl‐2 oncoprotein was decreased. These parameters identify the role of ADM expression and Bcl‐2 protein in relation to cell growth and vasodilating in the neoplastic changes.